Compare IDEXX Laboratories, Inc. (IDXX) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Lucid Group Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Lucid Group Inc trades at $3.79 (market cap $1.51B). The key difference: IDEXX Laboratories, Inc. is far larger — about 26.8× Lucid Group Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 12,333,745). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Lucid Group Inc for 45 Days on average.
| IDXX | LCID | |
|---|---|---|
Market Cap | $40.43B | $1.51B |
Volume | 692,164 | 12,333,745 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $21.92 |
52-Week Low | $504.70 | $3.82 |
Typical Hold Time | 46 Days | 45 Days |
Enterprise Value | $41.32B | $4.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Lucid Group (LCID) trades at $3.79, down 2.57% on the day, reflecting ongoing investor concerns about the company's financial performance. The stock shows bearish technical signals with negative moving averages and faces fundamental challenges including significant losses, negative profit margins, and cash burn. Recent news highlights management's focus on cost savings and strategic partnerships while delaying key product launches like the Cosmos SUV.
The outlook remains challenging with persistent losses and high cash burn requiring additional financing. Analyst consensus is cautious with only 13% buy ratings and a $7.60 price target representing potential upside. Key risks include execution delays, competitive pressure, and potential dilution from future capital raises.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
